| 000 | 00000nam##2200000za#4500 |
| 001 | 9.688015 |
| 003 | CaOODSP |
| 005 | 20210624231232 |
| 007 | cr ||||||||||| |
| 008 | 150407|2005||||xxc|||||o f|0| 0 eng|d |
| 020 | |a0-662-42457-3 |
| 040 | |aCaOODSP|beng |
| 043 | |an-cn--- |
| 086 | 1 |aH169-2/2005E-PDF |
| 110 | 1 |aCanada.|bHealth Canada. |bTherapeutic Products Directorate. |
| 245 | 10|aGuidance for industry : |h[electronic resource]|bmanagement of drug submissions |
| 260 | |aOttawa - Ontario : |bHealth Canada. |c2005. |
| 300 | |a41p.|bglossary, table |
| 500 | |aThe catalogue number (H169-2/2005E) and ISBN (0-662-42456-5) for the print edition have been incorrectly copied in this electronic publication. |
| 590 | |a07-07|b2007-02-16 |
| 690 | 07|aApproval processes|2gcpds |
| 690 | 07|aDrugs|2gcpds |
| 775 | 08|tLigne directrice à l'intention de l'industrie : |w(CaOODSP)9.632456 |
| 794 | |tGuidance document : |w(CaOODSP)9.873424 |
| 856 | 40|ahttp://publications.gc.ca|qPDF|s636 KB|uhttps://publications.gc.ca/collections/Collection/H169-2-2005E.pdf |